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1. INTRODUCTION {#mgg3538-sec-0005}
===============

Glaucoma, characterized by atrophy of optic nerve and progressive loss of sight, is one of the leading causes of blindness all over the world (Mantravadi & Vadhar, [2015](#mgg3538-bib-0009){ref-type="ref"}). Over the past two decades, the prevalence of glaucoma has significantly increased, and according to an epidemiological study, it is estimated that glaucoma would affect over 80 million people by 2020 (Weinreb, Aung, & Medeiros, [2014](#mgg3538-bib-0015){ref-type="ref"}). So far, the exact cause of glaucoma is still largely unclear. Nevertheless, the fact that multiple genetic loci have found to be correlated with individual susceptibility to this disease suggested that genetic factors play crucial roles in the occurrence and development of glaucoma (Asefa, Neustaeter, Jansonius, & Snieder, [2018](#mgg3538-bib-0002){ref-type="ref"}; Cissé, Bai, & Meng, [2018](#mgg3538-bib-0004){ref-type="ref"}; Wiggs & Pasquale, [2017](#mgg3538-bib-0016){ref-type="ref"}).

Methylenetetrahydrofolate reductase (MTHFR) is a central regulator of folate metabolism and homocysteine synthesis (Trimmer, [2013](#mgg3538-bib-0014){ref-type="ref"}). Previous studies have demonstrated that MTHFR deficiency could lead to hyperhomocysteinemia and give rise to the development of multiple vascular and neurodegenerative disorders including glaucoma (Li, Xu, Zeng, Gong, & Lan, [2016](#mgg3538-bib-0007){ref-type="ref"}; Zacharaki et al., [2014](#mgg3538-bib-0019){ref-type="ref"}). As a result, functional *MTHFR* (NG_013351.1) polymorphisms are thought to be ideal candidate genetic biomarkers of glaucoma.

Until now, some pilot studies have investigated possible correlations of *MTHFR* rs1801131 (A1298C) and rs1801133 (C677T) polymorphisms with glaucoma, but the results of these studies were conflicting and the sample size of individual studies was relatively small (Al‐Shahrani et al., [2016](#mgg3538-bib-0001){ref-type="ref"}; Buentello‐Volante et al., [2013](#mgg3538-bib-0003){ref-type="ref"}; Gupta et al., [2014](#mgg3538-bib-0005){ref-type="ref"}; Nilforoushan et al., [2012](#mgg3538-bib-0011){ref-type="ref"}). Therefore, we performed the present meta‐analysis to better elucidate the relation between *MTHFR* polymorphisms and glaucoma.

2. MATERIALS AND METHODS {#mgg3538-sec-0006}
========================

2.1. Ethical compliance {#mgg3538-sec-0007}
-----------------------

This article does not contain any studies with human participants or animals performed by any of the authors, so ethical approval is not required.

2.2. Literature search and inclusion criteria {#mgg3538-sec-0008}
---------------------------------------------

The current meta‐analysis was adhered to the Preferred Reporting Items for Systematic Reviews and Meta‐analyses (PRISMA) guideline (Moher, Liberati, Tetzlaff, Altman, & PRISMA group., [2009](#mgg3538-bib-0010){ref-type="ref"}). PubMed, Medline, and Embase were searched for relative articles published before September 2018 using the following strategy: (*methylenetetrahydrofolate reductase* OR *MTHFR*) AND (polymorphism OR variant OR mutation OR genotype OR allele) AND (primary open‐angle glaucoma OR POAG OR primary closed angle glaucoma OR PCAG OR pseudoexfoliation glaucoma OR PXFG OR glaucoma). The reference lists of all retrieved publications were also manually screened to identify other potentially relevant articles.

To test the research hypothesis of this meta‐analysis, included studies should meet all the following criteria: (a) case--control study on correlation between *MTHFR* polymorphisms and the likelihood of glaucoma; (b) provide adequate data to calculate odds ratios (ORs) and 95% confidence intervals (CIs); (c) full text in English or Chinese available. Studies were excluded if one of the following criteria was fulfilled: (a) not relevant to *MTHFR* polymorphisms and glaucoma; (b) family‐based association studies; (c) case reports or case series; (d) abstracts, reviews, comments, letters, and conference presentations. For duplicate reports, we only included the study with the largest sample size for analyses.

2.3. Data extraction and quality assessment {#mgg3538-sec-0009}
-------------------------------------------

The following data were extracted from all included studies: (a) name of first author; (b) year of publication; (c) country and ethnicity of participants; (d) the number of cases and controls; and (e) the genotypic distribution of *MTHFR* polymorphisms in cases and controls. Additionally, the probability value (*p* value) of Hardy--Weinberg equilibrium (HWE) was also calculated. The Newcastle‐Ottawa scale (NOS) was used to assess the quality of eligible studies (Stang, [2010](#mgg3538-bib-0013){ref-type="ref"}). The NOS has a score range of zero to nine, and studies with a score of more than seven were thought to be of high quality. Two reviewers conducted data extraction and quality assessment independently. When necessary, the reviewers wrote to the corresponding authors for extra information or raw data. Any disagreement between two reviewers was solved by discussion until a consensus was reached.

2.4. Statistical analysis {#mgg3538-sec-0010}
-------------------------

All statistical analyses were conducted with Review Manager Version 5.3.3 (The Cochrane Collaboration, Software Update, Oxford, United Kingdom). ORs and 95% CIs were calculated to assess potential associations of *MTHFR* polymorphisms with the likelihood of glaucoma in all possible genetic models, and a *p* value of 0.05 or less was considered to be statistically significant. Between‐study heterogeneities were evaluated with *I* ^2^ statistic. If *I* ^2^ was greater than 50%, random‐effect models (REMs) would be used to pool the data in overall and subgroup analyses. Otherwise, fixed‐effect models (FEMs) would be employed for synthetic analyses. Sensitivity analyses were carried out to test the stability of our findings. Funnel plots were applied to evaluate possible publication bias.

3. RESULTS {#mgg3538-sec-0011}
==========

3.1. Characteristics of included studies {#mgg3538-sec-0012}
----------------------------------------

The literature search generated 144 results. After exclusion of irrelevant and duplicate articles by reading titles and abstracts, 30 articles were retrieved for further evaluation. Another 12 articles were subsequently excluded after reading the full text. Finally, a total of 18 eligible studies containing 3,453 cases and 3,715 controls were included for analyses (see Figure [1](#mgg3538-fig-0001){ref-type="fig"}). Characteristics of included studies were summarized in Table [1](#mgg3538-tbl-0001){ref-type="table"}.

![Flowchart of study selection for the present study](MGG3-7-na-g001){#mgg3538-fig-0001}

###### 

The characteristics of included studies

  First author, year        Country        Ethnicity    Type of disease   Sample size   Genotype distribution   *p*‐value for HWE   NOS score   
  ------------------------- -------------- ------------ ----------------- ------------- ----------------------- ------------------- ----------- ---
  rs1801131                                                                                                                                     
  Fan, 2008                 USA            Mixed        PXFG              158/50        74/58/26                22/19/9             0.191       7
  Mabuchi, 2006             Japan          East Asian   POAG              264/106       167/94/3                61/44/1             0.023       7
  Micheal, 2009             Pakistan       West Asian   POAG              173/143       35/114/24               20/97/26            \<0.001     7
  Micheal, 2009             Pakistan       West Asian   PCAG              122/143       34/76/12                20/97/26            \<0.001     7
  Woo, 2009                 Korea          East Asian   POAG              78/100        57/19/2                 75/22/3             0.388       8
  Zacharaki, 2014           Greece         Caucasian    POAG              66/133        33/27/6                 64/56/13            0.883       8
  Zacharaki, 2014           Greece         Caucasian    PXFG              74/133        31/32/11                64/56/13            0.883       8
  Zetterberg, 2007          Sweden         Caucasian    POAG              243/187       119/97/27               88/87/12            0.117       7
  rs1801133                                                                                                                                     
  Al‐Shahrani, 2016         Saudi Arabia   West Asian   POAG              144/280       88/56/0                 210/70/0            0.017       8
  Al‐Shahrani, 2016         Saudi Arabia   West Asian   PCAG              66/280        49/17/0                 210/70/0            0.017       8
  Bleich, 2002              Germany        Caucasian    POAG              18/19         5/11/2                  13/5/1              0.588       7
  Buentello‐Volante, 2013   Mexico         Mixed        POAG              118/100       42/53/23                34/49/17            0.927       7
  Clement, 2009             Australia      Caucasian    POAG              70/42         38/25/7                 25/14/3             0.598       8
  Clement, 2009             Australia      Caucasian    PXFG              48/42         18/23/7                 25/14/3             0.598       8
  Fan, 2008                 USA            Mixed        PXFG              168/50        66/82/20                21/22/7             0.750       7
  Fan, 2010                 China          East Asian   POAG              397/201       244/137/16              135/60/6            0.830       7
  Fingert, 2006             USA            Mixed        POAG              178/166       72/77/29                75/73/18            0.970       7
  Fingert, 2006             USA            Mixed        PXFG              45/166        12/29/4                 75/73/18            0.970       7
  Gupta, 2014               India          West Asian   POAG              144/173       101/35/8                137/34/2            0.946       8
  Gupta, 2014               India          West Asian   PCAG              87/173        73/14/0                 137/34/2            0.946       8
  Jünemann, 2005            Germany        Caucasian    POAG              76/71         32/37/7                 45/24/2             0.569       7
  Jünemann, 2005            Germany        Caucasian    PXFG              71/71         36/29/6                 45/24/2             0.569       7
  Mabuchi, 2006             Japan          East Asian   POAG              264/106       105/113/46              48/39/19            0.035       7
  Micheal, 2009             Pakistan       West Asian   POAG              173/143       123/49/1                101/41/1            0.144       7
  Micheal, 2009             Pakistan       West Asian   PCAG              122/143       84/26/12                101/41/1            0.144       7
  Mossbock, 2006            Austria        Caucasian    POAG              204/211       119/71/14               105/86/20           0.696       7
  Mossbock, 2006            Austria        Caucasian    PXFG              138/211       72/50/16                105/86/20           0.696       7
  Nilforoushan, 2012        Iran           West Asian   POAG              73/90         39/28/6                 53/33/4             0.688       8
  Nilforoushan, 2012        Iran           West Asian   PXFG              85/90         46/31/8                 53/33/4             0.688       8
  Shi, 2013                 China          East Asian   PCAG              231/306       81/106/44               93/152/61           0.938       8
  Turaçli, 2005             Turkey         Caucasian    PXFG              76/34         39/31/6                 18/12/4             0.382       7
  Woo, 2009                 Korea          East Asian   POAG              78/100        25/34/19                31/50/19            0.884       8
  Zacharaki, 2014           Greece         Caucasian    POAG              64/130        22/31/11                39/70/21            0.264       8
  Zacharaki, 2014           Greece         Caucasian    PXFG              72/130        29/33/10                39/70/21            0.264       8
  Zetterberg, 2007          Sweden         Caucasian    POAG              243/187       126/97/20               89/75/23            0.252       7

HWE, Hardy--Weinberg equilibrium; NA, Not available; NOS, Newcastle‐Ottawa scale; PCAG, Primary closed angle glaucoma; POAG, Primary open‐angle glaucoma; PXFG, Pseudoexfoliation glaucoma.
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3.2. Overall and subgroup analyses {#mgg3538-sec-0013}
----------------------------------

A total of 18 studies with 7,168 participants were analyzed. In overall analyses, a significant association with the likelihood of glaucoma was detected for the rs1801133 polymorphism in dominant (*p* = 0.04, OR = 0.90, 95%CI 0.81--1.00) and allele (*p* = 0.02, OR = 0.91, 95%CI 0.84--0.98) comparisons. Further subgroup analyses by ethnicity revealed that both rs1801131 and rs1801133 polymorphisms were significantly associated with the likelihood of glaucoma in West Asians. However, no positive results were detected for two investigated polymorphisms in East Asians and Caucasians. When we stratified data based on type of disease, we found that the rs1801133 polymorphism was also significantly associated with the likelihood of primary open‐angle glaucoma (POAG). No any other positive findings were observed in overall and subgroup analyses (see Table [2](#mgg3538-tbl-0002){ref-type="table"} and Data [S1](#mgg3538-sup-0001){ref-type="supplementary-material"}).

###### 

Results of overall and subgroup analyses for *MTHFR* polymorphisms and glaucoma

  Population      Sample size   Dominant comparison   Recessive comparison        Additive comparison   Allele comparison                                                                                                              
  --------------- ------------- --------------------- --------------------------- --------------------- ------------------- --------------------------- ----- ------ ------------------- ----- ----------- --------------------------- -----
  rs1801131 A/C                                                                                                                                                                                                                        
  Overall         1178/995      0.71                  0.95 (0.70--1.27)           19%                   0.07                1.19 (0.98--1.44)           21%   0.13   0.87 (0.72--1.04)   0%    0.15        0.91 (0.79--1.04)           20%
  East Asian      342/206       0.97                  0.98 (0.24--3.96)           0%                    0.50                1.14 (0.78--1.67)           0%    0.50   0.88 (0.60--1.29)   0%    0.55        0.91 (0.65--1.25)           0%
  West Asian      295/286       **0.04**              **0.62 (0.39**--**0.98)**   0%                    **0.003**           **1.91 (1.24**--**2.94)**   0%    0.36   0.85 (0.60--1.20)   0%    **0.007**   **0.72 (0.58**--**0.92)**   0%
  Caucasian       383/453       0.09                  1.51 (0.94--2.42)           0%                    0.99                1.00 (0.75--1.32)           0%    0.32   0.87 (0.65--1.15)   0%    0.43        1.09 (0.88--1.35)           0%
  POAG            824/669       0.80                  1.05 (0.71--1.56)           0%                    0.20                1.16 (0.93--1.46)           20%   0.16   0.86 (0.69--1.07)   0%    0.40        0.93 (0.79--1.10)           0%
  PXFG            232/183       0.57                  1.19 (0.65--2.18)           0%                    0.68                0.92 (0.60--1.40)           0%    0.99   1.00 (0.65--1.55)   0%    0.55        1.10 (0.81--1.52)           15%
  rs1801133 C/T                                                                                                                                                                                                                        
  Overall         3453/3715     **0.04**              **0.90 (0.81**--**1.00)**   43%                   0.08                1.16 (0.98--1.38)           9%    0.30   1.06 (0.95--1.17)   28%   **0.02**    **0.91 (0.84**--**0.98)**   45%
  East Asian      970/713       0.58                  0.94 (0.76--1.16)           22%                   0.74                1.05 (0.78--1.42)           0%    0.76   1.03 (0.84--1.27)   22%   0.57        0.96 (0.82--1.11)           0%
  West Asian      894/1372      **0.02**              **0.80 (0.66**--**0.97)**   20%                   **\<0.001**         **3.07 (1.64**--**5.76)**   18%   0.29   1.11 (0.91--1.35)   36%   **0.002**   **0.77 (0.65**--**0.91)**   25%
  Caucasian       1080/1148     0.40                  0.88 (0.65--1.18)           61%                   0.94                1.01 (0.76--1.34)           0%    0.99   1.00 (0.84--1.19)   32%   0.34        0.90 (0.71--1.13)           62%
  POAG            2244/2019     **0.02**              **0.86 (0.76**--**0.98)**   50%                   0.19                1.16 (0.93--1.46)           2%    0.13   1.10 (0.97--1.26)   33%   **0.04**    **0.85 (0.73**--**1.00)**   53%
  PCAG            506/902       0.35                  1.13 (0.88--1.45)           0%                    0.54                1.87 (0.25--13.87)          74%   0.15   0.84 (0.65--1.07)   0%    0.76        1.03 (0.85--1.25)           34%
  PXFG            703/794       0.16                  0.85 (0.69--1.06)           44%                   0.45                1.15 (0.80--1.64)           0%    0.34   1.11 (0.89--1.39)   31%   0.15        0.89 (0.75--1.05)           33%

CI, Confidence interval; NA, Not available; OR, Odds ratio; POAG, Primary open‐angle glaucoma; PCAG, Primary closed angle glaucoma; PXFG, Pseudoexfoliation glaucoma.

*MTHFR*, NCBI Reference Sequence: NG_013351.1

The values in bold represent there are statistically significant differences between cases and controls.
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3.3. Sensitivity analyses {#mgg3538-sec-0014}
-------------------------

Sensitivity analyses were conducted to examine the stability of synthetic results by eliminating studies that deviated from HWE. No changes of results were found in any comparisons, which indicated that our findings were statistically reliable.

3.4. Publication biases {#mgg3538-sec-0015}
-----------------------

Potential publication biases in the current study were evaluated with funnel plots. No obvious asymmetry of funnel plots was observed in any comparisons, which suggested that our findings were unlikely to be influenced by severe publication bias.

4. DISCUSSION {#mgg3538-sec-0016}
=============

To the best of our knowledge, this is so far the most comprehensive meta‐analysis on correlations between *MTHFR* polymorphisms and glaucoma. The overall and subgroup analyses revealed that rs1801131 and rs1801133 polymorphisms were both significantly associated with the likelihood of glaucoma in West Asians. Nevertheless, no positive results were detected for two investigated polymorphisms in East Asians and Caucasians. The stability of synthetic results was subsequently evaluated in sensitivity analyses, and no changes of results were observed in any comparisons, which indicated that our findings were quite stable and reliable.

There are several points that need to be addressed about this meta‐analysis. Firstly, no obvious heterogeneities were detected in overall analyses for two investigated polymorphisms, which indicated that eligible studies could be considered as homogeneous, and thus synthesize the results of these studies is statistically feasible. Secondly, previous experimental studies have shown that the C to T substitution of rs1801133 (substitution of valine for alanine) and A to C substitution of rs1801131 (substitution of glutamate for alanine) could lead to reduced enzymatic activity and result in hyperhomocysteinemia, which may partially explain our positive findings (Li et al., [2017](#mgg3538-bib-0006){ref-type="ref"}; Li, Dai, Zheng, Liu, & Huang, [2015](#mgg3538-bib-0008){ref-type="ref"}). Thirdly, the pathogenic mechanism of glaucoma is quite complex, and hence it is unlikely that a single gene polymorphism can significantly contribute to its development. Therefore, to better illustrate potential correlations of certain gene polymorphisms with glaucoma, we strongly recommend further studies to perform haplotype analyses and explore potential gene--gene interactions.

As with all meta‐analysis, this study certainly has some limitations. First, our findings were based on unadjusted analyses due to lack of raw data, and failure to conduct further adjusted analyses for age, gender, and co‐morbidity conditions may impact the reliability of our findings (Shi, Xie, Jia, & Li, [2016](#mgg3538-bib-0012){ref-type="ref"}; Xie, Shi, Xun, & Rao, [2017](#mgg3538-bib-0018){ref-type="ref"}). Second, association between *MTHFR* polymorphisms and glaucoma may be affected by gene--gene and gene--environmental interactions. However, the majority of studies did not consider these potential interactions, which impeded us to perform relevant analyses accordingly (Xie, Shi, & Liu, [2017](#mgg3538-bib-0018){ref-type="ref"}). Third, only retrospective case--control studies were included in this meta‐analysis, and thus direct causal relation between *MTHFR* polymorphisms and glaucoma could not be established (Zhao, Yin, Wang, & Si, [2015](#mgg3538-bib-0020){ref-type="ref"}). Taken these limitations into consideration, the results of the current study should be interpreted with caution.

Overall, our meta‐analysis suggested that rs1801131 and rs1801133 polymorphisms may serve as genetic biomarkers of glaucoma in West Asians. However, further well‐designed studies are still warranted to confirm our findings.
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